FOXO4-DRI – 10mg

FOXO4-DRI Peptide in Experimental Conditions

This product is not intended for weight loss, human consumption, or veterinary use. It is sold for research purposes only. Please handle with care and follow all safety guidelines for the specific chemicals involved.

What Is FOXO4-DRI?

FOXO4-DRI (Forkhead box O4 D-Retro-Inverso) is a synthetic peptide engineered to disrupt the interaction between the transcription factor FOXO4 and the tumor suppressor p53. This interaction normally helps senescent cells evade apoptosis; by competitively inhibiting it, FOXO4-DRI triggers targeted apoptosis of senescent cells, classifying it as a senolytic agent. Mechanistically, FOXO4-DRI causes nuclear exclusion of p53 and promotes mitochondrial apoptosis specifically in senescent cells while sparing healthy cells, making it a valuable tool for studying the consequences of senescent cell clearance in vivo and in vitro. (Wikipedia)

FOX04-DRI in Aging and Senescence Research

In experimental settings, FOXO4-DRI has been widely studied in rodent models to investigate the role of senescent cells in aging and disease. For example, in naturally aged mice, systemic administration of FOXO4-DRI reduced markers of senescence in testicular tissue and improved physiological outcomes such as testosterone secretion, suggesting potential therapeutic benefits in age-related hypogonadism. These effects were linked to decreased senescence-associated proteins (p53, p21, p16) and lower pro-inflammatory signaling in the testicular microenvironment. (PubMed)

Preclinical and In Vitro Research Findings

While specific PubMed entries for rat studies of FOXO4-DRI remain limited, foundational work in mouse models provides important context for translational research across rodent systems. In vitro studies using human and rodent cells confirm that FOXO4-DRI selectively eliminates senescent cells without broadly compromising normal cell viability. Additionally, research on related peptide inhibitors that target FOXO4-p53 interactions further supports the concept of peptide-based senolytics inducing apoptosis in senescent cells in vivo. (ScienceDirect)

Research Summary

Overall, FOXO4-DRI represents a powerful investigative tool in preclinical aging and senescence research, with ongoing work needed to characterize its pharmacodynamics and safety in rat models under controlled experimental conditions.

PubMed References (APA)

Baar, M. P., Brandt, R. M. C., Putavet, D. A., Klein, J. D. D., Derks, K. W. J., Bourgeois, B. R. M., … van Deursen, J. M. (2017). Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging. Cell, PMID: 28297709. (PMC)

Zhang, C., et al. (2020). FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice. Aging (Albany NY), PMID: 31959736. (PubMed)

Huang, Y., He, Y., Makarcyzk, M. J., & Lin, H. (2021). Senolytic peptide FOXO4-DRI selectively removes senescent cells from in vitro expanded human chondrocytes. Frontiers in Bioengineering and Biotechnology, PMID: 33996787. (PubMed)